|
Title
|
Published
|
Price
|
|
United States Type 2 Diabetes Market
By: Intellent
Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market
|
more...
Search inside this report
|
11/14/2009
|
$7,500.00
|
|
Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies
By: Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces
|
more...
|
11/1/2009
|
$25,800.00
|
|
UAE Healthcare Sector Forecast to 2012
By: RNCOS
The UAE has emerged as one the fastest growing healthcare markets in the Middle East. The country’s healthcare sector has grown at double digit rate to keep pace with incessantly rising demand for quality treatment
|
more...
|
11/1/2009
|
$1,000.00
|
|
CDK Inhibitors Patent Landscape 2009
By: France Innovation Scientifique et Transfer
IP Overview presents a patent landscape analysis of the CDK Inhibitor field.
Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative
|
more...
Search inside this report
|
10/29/2009
|
$1,645.00
|
|
Antidiabetics in Australia Market Forecast
By: Datamonitor
Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest
|
more...
|
10/20/2009
|
$5,700.00
|
|
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
By: Datamonitor
Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest
|
more...
|
10/20/2009
|
$5,700.00
|
|
Blood, Organ & Ambulatory Health Services in the US - Industry Risk Rating Report
By: IBISWorld
Industry Risk Ratings Synopsis This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Blood, Organ & Ambulatory Health Services in the US industry. Industry Risk is assumed to be 'the difficulty,
|
more...
Search inside this report
|
10/17/2009
|
$825.00
|
|
Antidiabetics Market Forecast
By: Datamonitor
Introduction Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists,
|
more...
|
10/8/2009
|
$15,200.00
|
|
Commercial Insight: Antidiabetics - DPP-IV inhibitors poised to sweep the market
By: Datamonitor
Introduction Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists,
|
more...
|
10/2/2009
|
$15,200.00
|
|
Pipeline Insight: HIV - The Age of Convenience
By: Datamonitor
Introduction Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard
|
more...
|
10/2/2009
|
$11,400.00
|
|
The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
By: Kalorama Information
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness
|
more...
|
10/1/2009
|
$3,500.00
|
|
Analgesics in Denmark
By: Euromonitor International
Euromonitor International's Analgesics in Denmark report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the
|
more...
Search inside this report
|
10/1/2009
|
$900.00
|
|
Minimally Invasive and Non Invasive Surgery Market (2009 - 2014)
By: MarketsandMarkets
The healthcare industry has recently witnessed the adoption of many new technologies that increase the efficiency of various medical treatments. Minimally invasive surgery (MIS) is one of the most important developments among all such cutting-edge
|
more...
|
10/1/2009
|
$4,650.00
|
|
Infectious Diseases Drugs Markets
By: Trimark Publications
According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. What’s more, threatening pandemics such
|
more...
|
10/1/2009
|
$3,400.00
|
|
Diabetes R & D Pipeline: PPAR Agonists
By: BioPolaris
Diabetes is a chronic disease that may reduce life expectancy by as much as 15 years because high blood
glucose levels can damage blood vessels and nerves. The International Diabetes Institute (Australia) estimates
that direct
|
more...
Search inside this report
|
10/1/2009
|
$650.00
|
|
Diabetes R & D Pipeline: GLP-1 Agonists, Analogs and Allosteric Modulators
By: BioPolaris
The worldwide market for anti-diabetic therapeutic products is large and highly competitive. The global antidiabetic market is estimated to be over $24 billion in 2008. The largest players in this market are AstraZeneca plc (UK),
|
more...
Search inside this report
|
10/1/2009
|
$950.00
|
|
Analgesics in Venezuela
By: Euromonitor International
Euromonitor International's Analgesics in Venezuela report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the
|
more...
Search inside this report
|
10/1/2009
|
$900.00
|
|
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?
By: Decision Resources
Introduction
“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a
|
more...
|
9/23/2009
|
$4,500.00
|
|
World Neurodegenerative Diseases Market 2009-2024
By: Visiongain
The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market.
|
more...
|
9/18/2009
|
$2,502.00
|
|
Metabolic Endocrinology Type II Diabetes Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Type II Diabetes Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of type ii diabetes drugs by company and by
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Metabolic Endocrinology Type I Diabetes Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Type I Diabetes Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of type i diabetes drugs by company and by
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Metabolic Endocrinology Obesity Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Obesity Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of obesity drugs by company and by stage as well as
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Metabolic Endocrinology Diabetic Neuropathy Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Diabetic Neuropathy Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of diabetic neuropathy drugs by company and by stage as
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Infections Tuberculosis Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Tuberculosis Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of tuberculosis drugs by company and by stage as well as
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Infections Herpes Simplex Virus Infection Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Herpes Simplex Virus Infection Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of herpes simplex virus infection drugs by company
|
more...
Search inside this report
|
9/14/2009
|
$1,495.00
|
|
Title
|
Published
|
Price
|
(0 items)
